The role of IL-29 in immunity and cancer

  • Crit Rev Oncol Hematol. 2016 Oct;106:91-8. doi: 10.1016/j.critrevonc.2016.08.002.
Noah E Kelm  1 ,  Ziwen Zhu  2 ,  Vivi A Ding  1 ,  Huaping Xiao  3 ,  Mark R Wakefield  2 ,  Qian Bai  2 ,  Yujiang Fang  4
Affiliations
  • 1. Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States.
  • 2. Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, United States.
  • 3. Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States; The Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China.
  • 4. Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA 50312, United States; Department of Surgery, University of Missouri School of Medicine, Columbia, MO 65212, United States. Electronic address: [email protected].
PMID: 27637354 DOI: 10.1016/j.critrevonc.2016.08.002
Abstract

Interleukin-29 (IL-29) is a new member of the recently discovered interferon λ (IFNλ) family. It is produced predominantly by maturing dendritic cells and macrophages. It has been implicated in numerous immunological responses and has shown Antiviral activity similar to the Type I interferons, although its target cell population is more limited than the Type I interferons. In recent years, the role of IL-29 in the pathogenesis of various cancers has also been extensively studied. In this review, we will discuss the recent advances of IL-29 in immunological processes and the pathogenesis of various Cancer.

Keywords
Cancer; Cytokine; IL-29; Immune response.
Products